SCHEMBL6938836

SCHEMBL6938836

NC(=O)c1ccc(CNC(=O)c2cc([N+](=O)[O-])ccc2NC2CCCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
KMT2A Q03164 1/20 0.52
EPHX1 P07099 1/20 0.50
MITF O75030 1/20 0.49
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
HCAR3 P49019 2/20 0.47
SLC6A9 P48067 1/20 0.46
SLC6A5 Q9Y345 1/20 0.46
THRB P10828 1/20 0.45
CA2 P00918 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TBXA2R P21731 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6939682 0.92 MAPT (0.63) MAPTKMT2AEPHX1MITFSMN1; SMN2
SCHEMBL6943155 0.91 MAPT (0.60) MAPTKMT2AEPHX1SMN1; SMN2ALDH1A1
SCHEMBL6939688 0.90 MAPT (0.59) MAPTKMT2AEPHX1MITFRAB9A
SCHEMBL6939388 0.88 MAPT (0.59) MAPTKMT2AEPHX1SMN1; SMN2ALDH1A1
SCHEMBL6943662 0.88 MAPT (0.59) MAPTKMT2AEPHX1SMN1; SMN2ALDH1A1
SCHEMBL6939456 0.88 MAPT (0.59) MAPTKMT2AEPHX1SMN1; SMN2ALDH1A1
SCHEMBL6943163 0.88 MAPT (0.62) MAPTKMT2AEPHX1RAB9ASMN1; SMN2
SCHEMBL6943785 0.87 CA2 (0.57) MAPTKMT2AEPHX1SMN1; SMN2ALDH1A1
SCHEMBL6941716 0.87 MAPT (0.72) MAPTKMT2AEPHX1RAB9ASMN1; SMN2
SCHEMBL6937248 0.87 MAPT (0.72) MAPTKMT2AEPHX1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MAPT 4706/4885KMT2A 1991/4885EPHX1 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.